Tradestie Institutional Equity Comparison Engine
ETON vs DMAC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ETON Overall Edge
ETON Captures Institutional Edge (4โ0 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Eton Pharmaceutcials, Inc. Common Stock (ETON) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ETON trades at 19.3x Forward P/E with 31.3% operating margin (+157.9% YoY revenue) versus DMAC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ETON sits in CONSOLIDATION (14th %ile IV; Dealer Gamma Walls on Pro) against DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
ETON
ETON 19.3x vs DMAC N/M Fwd P/E
Growth & Margin Winner
ETON
Op Margin 31.3% vs 0.0% ยท YoY +157.9% vs +0.0%
Momentum & Technical Winner
ETON
1Y +280.9% vs +55.3% ยท 52W Pos 89% vs 55%
Options & Structure Winner
ETON
CONSOLIDATION (14th %ile IV) vs SURGE (14th %ile IV)
ETON
NASDAQ
Eton Pharmaceutcials, Inc. Common Stock
Pharmaceutical Preparations
$64.30
+0.58% 1D
Market Cap
$1.8B
1M Return
+27.81%
1Y Return
+280.92%
Forward P/E
19.3x
Unified AI Score
36.5 / 100
SELL
Tech 50.0
Fund 36.0
Flow 70.0
Mom 50.0
DMAC
NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap
$503.1M
1M Return
+11.16%
1Y Return
+55.26%
Forward P/E
N/M
Unified AI Score
46.3 / 100
HOLD
Tech 30.0
Fund 51.0
Flow 65.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ETON +280.92%
DMAC +55.26%
Spread: +225.66 pp (ETON Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ETON Revenue | DMAC Revenue | ETON Op. Margin | DMAC Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -1352.2% | DMAC |
| FY2019 | $0M | N/A | -1939.6% | N/A | ETON |
| FY2020 | $0M | N/A | -69515.4% | N/A | ETON |
| FY2021 | $20M | N/A | -6.8% | N/A | ETON |
| FY2022 | $20M | N/A | -38.9% | N/A | ETON |
| FY2023 | $30M | N/A | -3.8% | N/A | ETON |
| FY2024 | $40M | N/A | -6.7% | N/A | ETON |
| FY2025 | $80M | N/A | -1.1% | N/A | ETON |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ETON | DMAC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.8B | $503.1M | Larger Scale | ETON |
| Trailing P/E Ratio Valuation | 39.9x | N/M | Lower Multiple | ETON |
| Forward P/E Ratio Valuation | 19.3x | N/M | Lower Multiple | ETON |
| Revenue Growth (YoY) Growth | +157.9% | +0.0% | Higher Growth | ETON |
| Operating Margin (TTM) Profitability | 31.3% | 0.0% | Higher Margin | ETON |
| Net Profit Margin Profitability | 35.4% | 0.0% | Higher Margin | ETON |
| Return on Equity (ROE) Capital Efficiency | 90.6% | -114.6% | Higher ROE | ETON |
| 52-Week Range Position Momentum | 89% ($14โ$71) | 55% ($5โ$11) | Stronger Trend | ETON |
| Beta / 30D Volatility Risk Regime | 0.63ฮฒ ยท 99% Vol | 1.74ฮฒ ยท 98% Vol | Lower Realized Risk | DMAC |
| Unified Institutional Score Composite Signal | 36.5 / 100 (SELL) | 46.3 / 100 (HOLD) | Higher Composite | DMAC |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ETON vs DMAC Buy Guide
ETON
CONSOLIDATION
59d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
14th %ile
IV Regime
Compressed (<25th %ile)
DMAC
SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
14th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ETON nor DMAC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.